Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
Related Tickers: APVO
TL;DR
APVO filed an 8-K on 12/12/24. No major news yet.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on December 12, 2024, to report other events and financial statements. The filing does not contain specific details about new material events or financial figures within the provided text.
Why It Matters
This filing indicates that Aptevo Therapeutics Inc. is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and corporate actions.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosed material changes.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- December 12, 2024 (date) — Date of Report
- 206-838-0500 (phone_number) — Business Phone
FAQ
What specific 'Other Events' are being reported by Aptevo Therapeutics Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
When was this 8-K report filed by Aptevo Therapeutics Inc.?
This 8-K report was filed on December 12, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive offices are located at 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
Does the filing mention any specific financial results or figures?
The filing indicates that 'Financial Statements and Exhibits' are included, but the provided text does not detail specific financial results or figures.
Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-12 09:05:40
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20241212.htm (8-K) — 40KB
- apvo-ex99_1.htm (EX-99.1) — 27KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-135609.txt ( ) — 195KB
- apvo-20241212.xsd (EX-101.SCH) — 25KB
- apvo-20241212_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 12, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") issued a press release announcing 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease negative status (100% elimination of cancer cells). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: December 12, 2024 By: /s/ Marvin L. White President and Chief Executive Officer